{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-039261","form_type":"8-K","ticker":"BAX","cik":"0000010456","company_name":"BAXTER INTERNATIONAL INC","filed_at":"2023-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.649290+00:00","generated_at":"2026-06-19T12:56:49.427125+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Baxter announces director retirements, new executives, and cash severance policy","bullets":["Thomas F. Chen and Albert P.L. Stroucken retiring from board effective April 28, 2023.","Cathy R. Smith to chair Nominating, Governance & Public Policy; Peter Wilver to chair Audit.","D. Brent Shafer appointed Lead Independent Director effective April 28, 2023.","New executives: Heather Knight, Reaz Rasul, Alok Sonig as group presidents effective March 1, 2023.","Cash severance policy caps new executive benefits at 2.99x base salary plus target bonus without shareholder vote."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-039261","json":"https://secwatch.observer/filing/0001193125-23-039261.json","markdown":"https://secwatch.observer/filing/0001193125-23-039261.md","text":"https://secwatch.observer/filing/0001193125-23-039261.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/10456/000119312523039261/0001193125-23-039261-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10456/000119312523039261/d465899d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T12:56:49.427125+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7c492efcf0","claim":"Reaz Rasul was appointed as Executive Vice President and Group President, Healthcare Systems and Technologies at BAXTER INTERNATIONAL INC.","evidence_excerpt":"Mr. Reaz Rasul was appointed as the Company’s Executive Vice President and Group President, Healthcare Systems and Technologies.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/10456/000119312523039261/0001193125-23-039261-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President and Group President, Healthcare Systems and Technologies"}],"fact_type":"executive_change"},{"claim_id":"9f886d5ed0","claim":"Thomas F. Chen retired as Director at BAXTER INTERNATIONAL INC.","evidence_excerpt":"On February 13, 2023, Mr. Thomas F. Chen notified Baxter International Inc. (the “Company” or “Baxter”) of his decision to retire from the Board of Directors of the Company (the “Board”), effective as of April 28, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/10456/000119312523039261/0001193125-23-039261-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a8d9e70942","claim":"D. Brent Shafer was appointed as Lead Independent Director at BAXTER INTERNATIONAL INC.","evidence_excerpt":"the Board also appointed Mr. D. Brent Shafer as the Board’s Lead Independent Director, effective April 28, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/10456/000119312523039261/0001193125-23-039261-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Lead Independent Director"}],"fact_type":"executive_change"},{"claim_id":"b4f739aae5","claim":"Alok Sonig was appointed as Executive Vice President and Group President, Pharmaceuticals at BAXTER INTERNATIONAL INC.","evidence_excerpt":"Mr. Alok Sonig was appointed as the Company’s Executive Vice President and Group President, Pharmaceuticals.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/10456/000119312523039261/0001193125-23-039261-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President and Group President, Pharmaceuticals"}],"fact_type":"executive_change"},{"claim_id":"bfb80e4792","claim":"Albert P.L. Stroucken retired as Director at BAXTER INTERNATIONAL INC.","evidence_excerpt":"Mr. Stroucken’s term will expire on April 28, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/10456/000119312523039261/0001193125-23-039261-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e368a5567a","claim":"Heather Knight was appointed as Executive Vice President and Group President, Medical Products and Therapies at BAXTER INTERNATIONAL INC.","evidence_excerpt":"Ms. Heather Knight was appointed as the Company’s Executive Vice President and Group President, Medical Products and Therapies.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/10456/000119312523039261/0001193125-23-039261-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President and Group President, Medical Products and Therapies"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}